CREB/ATF1 activation antagonized the anti-cancer effects of aspirin, and pharmacological targeting of CREB/ATF1 significantly enhanced the efficacy of aspirin against HCC cancer cells. Here, CREB1 is linked to hepatocellular carcinoma.